Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Small Cell Lung Carcinoma 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 8Neuroblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Myelodysplastic Syndromes 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Unspecified Adult Solid Tumor, Protocol Specific 3Sarcoma 3Polycythemia Vera 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Ganglioneuroblastoma 3Carcinoma, Non-Small-Cell Lung 3Anemia, Refractory, with Excess of Blasts 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Neuroendocrine 2

Interventions

dinutuximab 4sargramostim 3Topotecan 3Cyclophosphamide 3Colony-Stimulating Factors 3Vincristine 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Radiation 2Platinum 2Melphalan 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2Etoposide 2Doxorubicin 2Cisplatin 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1iberdomide 1Transurethral Resection of Bladder 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Ganglioneuroblastoma × Topotecan × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡